About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Lupus Clinical Trials in Phoenix | 165 Studies | Clareo Health

Clinical Trials LupusPhoenix

Lupus Clinical Trials in Phoenix

Find 165 clinical trials for lupus near Phoenix, Arizona. Connect with research centers in your area.

All Lupus trials nationwide All trials in Phoenix

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 21-40 of 165 trials

COMPLETEDPhase 3< 1 mile

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

NCT05113745

This study will evaluate the long-term efficacy and safety of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepiness (EDS).

NarcolepsyCataplexyExcessive Daytime Sleepiness

Axsome Therapeutics, Inc.68 participantsStarted Oct 2021

Phoenix, Arizona, United States • Boulder, Colorado, United States • Colorado Springs, Colorado, United States +22 more locations

TERMINATEDPhase 2< 1 mile

A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

NCT05814016

The main aim is to see if danavorexton can help improve people's breathing in the recovery room after abdominal surgery.

Takeda41 participantsStarted May 2023

Sheffield, Alabama, United States • Phoenix, Arizona, United States • La Jolla, California, United States +16 more locations

Lupus Trials in Other Cities

New York Los Angeles Chicago Houston Philadelphia San Antonio

Data from ClinicalTrials.govTerms

RECRUITINGNA< 1 mile

Adjunctive Bright Light Therapy for Opioid Use Disorder

NCT05459922

Investigators propose to conduct a pilot single-blind, parallel arm, randomized placebo-controlled trial evaluating the feasibility, acceptability, and preliminary efficacy of bright light therapy on reward system functioning among patients undergoing medication-assisted treatment for opioid use disorder.

Opioid Use DisorderSleep Disturbance

Arizona State University23 participantsStarted Oct 2022

Phoenix, Arizona, United States

RECRUITINGNA< 1 mile

Wellness Intervention for Smoking and HIV

NCT04725617

The investigators propose to use a parallel group, randomized controlled trial to test the efficacy of a 13-week personalized approach to reducing smoking intervention versus a second approach using a different health intervention on smoking cessation, healthy sleep metrics, and biomarkers of cardiovascular risk in a sample of 200 treatment-seeking smokers who are adults living with HIV (ALHIV). To enroll in the study, treatment-seeking ALHIV smokers will undergo phone and in-person study eligibility assessments, including a history, physical examination, screening laboratory tests, and an overnight in-home objective sleep assessment. Eligible subjects (N=200) will be randomized to the 13-week Approach 1 (N=100) or Approach 2 (N=100) condition. All subjects will receive a 12-week course of varenicline (beginning in week 2) and 8 individual 15-minute smoking cessation counseling sessions \[weeks 1, 2, 3 (target quit date), 5, 7, 9, 11, 13\]. At each in-person counseling session, 30-45 minutes of Approach 1 or Approach 2 counseling will be provided as well. While receiving varenicline, the study team will monitor for side effects and changes to blood pressure at each study visit for safety reasons. Study measures are collected at all time points including EOT (week 13), and 6-month follow-up (6MFU).

HIVSleepSmoking Cessation+1 more

University of Arizona200 participantsStarted Nov 2021

Phoenix, Arizona, United States • Tucson, Arizona, United States

COMPLETEDPhase 2< 1 mile

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

NCT04835441

This is Phase 2, multinational, randomized, blinded study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 (acazicolcept) in adults with moderate to severe active systemic lupus erythematosus (SLE)

Systemic Lupus Erythematosus

Alpine Immune Sciences Inc, A Subsidiary of Vertex76 participantsStarted Jun 2021

Anniston, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +43 more locations

RECRUITINGPhase 49.0 miles

Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial

NCT07225387

This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) compared to proportion of patients achieving CRR from recent clinical trials. This protocol will additionally determine whether combination therapy using Belimumab (BEL) and Voclosporin (VCS) facilitates rapid discontinuation of MMF.

Lupus Nephritis

NephroNet, Inc.30 participantsStarted Oct 2024

Glendale, Arizona, United States • Atlanta, Georgia, United States • Lawrenceville, Georgia, United States +4 more locations

RECRUITINGNA11 miles

App-Based Optimization of Long-Term CPAP Adherence and Quality of Life

NCT06381115

The purpose of this study is to optimize the time of CPAP usage to at least 6 hours a night for 6 nights per week for people who have OSA with the help of a smartphone application called SmartWell24. This application aims to target CPAP adherence.

Obstructive Sleep Apnea

Mayo Clinic40 participantsStarted Jun 2025

Scottsdale, Arizona, United States • Rochester, Minnesota, United States

RECRUITINGPhase 317 miles

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

NCT06568367

SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).

Excessive SleepinessShift-work Disorder

Axsome Therapeutics, Inc.520 participantsStarted Aug 2024

Cullman, Alabama, United States • Chandler, Arizona, United States • Tucson, Arizona, United States +37 more locations

Active Not RecruitingPhase 1108 miles

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

NCT06265220

AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies. This clinical trial will enroll adult patients with lupus nephritis Class III or IV either with or without the presence of Class V who relapsed or did not respond to previous standard of care treatment approaches, or other forms of refractory systemic lupus erythematosus. The primary objective is to assess the safety, tolerability and preliminary activity of AB-101 plus a B-cell depleting mAb (e.g., rituximab, obinutuzumab) after cyclophosphamide and fludarabine in adult subjects with relapsed/refractory lupus nephritis Class III or IV, with or without the presence of Class V, or other forms of refractory systemic lupus erythematosus. Patients will be assigned to receive either AB-101 alone as monotherapy or in combination with a B-cell depleting mAb (e.g., rituximab, obinutuzumab). All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and response status. Patients may receive up to 2 cycles of treatment spaced 24 weeks apart.

Lupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IVRefractory Systemic Lupus Erythematosus+1 more

Artiva Biotherapeutics, Inc.51 participantsStarted Apr 2024

Birmingham, Alabama, United States • Tucson, Arizona, United States • San Diego, California, United States +6 more locations

RECRUITING108 miles

Lupus Landmark Study: A Prospective Registry and Biorepository

NCT05934149

The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN).

Systemic Lupus Erythematosus (SLE)Lupus NephritisNeuropsychiatric Systemic Lupus Erythematosus

Lupus Research Alliance3,500 participantsStarted Jun 2023

Birmingham, Alabama, United States • Tucson, Arizona, United States • Beverly Hills, California, United States +18 more locations

Active Not RecruitingPhase 3204 miles

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296

This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.

Systemic Lupus Erythematosus

Hoffmann-La Roche303 participantsStarted Oct 2021

Anniston, Alabama, United States • Searcy, Arkansas, United States • Fullerton, California, United States +61 more locations

COMPLETEDPhase 2256 miles

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

NCT03742037

The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).

Systemic Lupus Erythematosus

Viatris Innovation GmbH427 participantsStarted Dec 2018

Anniston, Alabama, United States • La Jolla, California, United States • Los Alamitos, California, United States +145 more locations

RECRUITINGPhase 2304 miles

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

NCT06559163

This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).

Systemic Lupus Erythematosus

Zenas BioPharma (USA), LLC190 participantsStarted Sep 2024

Fresno, California, United States • Huntington Park, California, United States • La Jolla, California, United States +79 more locations

COMPLETEDPhase 2333 miles

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

NCT04625101

This is a phase 2, double-blind study to assess the efficacy, safety, tolerability, and pharmacokinetics of NBI-827104 when administered once daily for 13 weeks in pediatric subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS).

Epileptic EncephalopathyContinuous Spike and Wave During Sleep

Neurocrine Biosciences24 participantsStarted Apr 2021

Orange, California, United States • Aurora, Colorado, United States • Washington D.C., District of Columbia, United States +12 more locations

COMPLETEDPhase 2357 miles

Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

NCT02770170

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for phase III development.

Lupus Nephritis

Boehringer Ingelheim121 participantsStarted May 2016

Los Angeles, California, United States • Doral, Florida, United States • Kissimmee, Florida, United States +71 more locations

COMPLETEDPhase 2357 miles

Study of Anti-Malarials in Incomplete Lupus Erythematosus

NCT03030118

This project is a multicenter, randomized, placebo-controlled, double-blind clinical trial that is designed to test whether treating patients who are at risk for development of lupus with hydroxychloroquine can slow accumulation of disease features. Effects on clinical progression of symptoms, patient-reported outcomes and changes in the immune markers of response will be measured and toxicity of the treatment will be assessed. This trial is a first step in testing a prevention strategy for lupus.

Systemic Lupus Erythematosus

Milton S. Hershey Medical Center187 participantsStarted Dec 2017

Los Angeles, California, United States • Aurora, Colorado, United States • Great Neck, New York, United States +4 more locations

TERMINATEDPhase 2357 miles

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

NCT05306873

The primary purpose of this study is to evaluate the potential effectiveness of 24 weeks of MMF within previously discovered immunologically defined subsets of SLE patients. Treatment effects will be evaluated within the individual immunologically-homogenous subsets defined at screening. This study will also explore and compare pre-randomization gene expression patterns among responders and non-responders to MMF and MMF plus voclosporin, use comprehensive immunophenotyping to study the immunologic changes that accompany treatment- induced disease improvement and to better understand immunologic changes associated with the loss of clinical response.

Systemic Lupus Erythematosus

National Institute of Allergy and Infectious Diseases (NIAID)12 participantsStarted Nov 2022

Los Angeles, California, United States • New Haven, Connecticut, United States • Atlanta, Georgia, United States +7 more locations

TERMINATEDPhase 2366 miles

Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

NCT05591222

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severe active primary Discoid Lupus Erythematosus (DLE) refractory to standard of care.

Discoid Lupus Erythematosus

Amgen72 participantsStarted Dec 2022

North Little Rock, Arkansas, United States • Beverly Hills, California, United States • Fremont, California, United States +65 more locations

RECRUITINGNA1090 miles

CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms

NCT05663034

This study is a prospective two-arm, single blind randomized controlled trial design to compare the clinical effectiveness of telemedicine-delivered, 6-session, standardized cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based treatment for insomnia (MBTI) in treating insomnia symptoms and ameliorating depressive symptoms in persons with mild to moderate TBI and comorbid Post-Traumatic Stress Symptoms (PTSS) and insomnia symptoms in a 360 patients. Participants will undergo assessment (psychosocial questionnaires, neurocognitive testing, sleep monitoring) at baseline, at the end of treatment, and at 2-, 6- and 12-weeks post-treatment. The primary outcome is sleep as measured by the Insomnia Severity Index (ISI).

Traumatic Brain InjuryInsomniaDepression+7 more

Johns Hopkins University360 participantsStarted May 2024

Eglin Air Force Base, Florida, United States • Eglin Air Force Base, Florida, United States • Bethesda, Maryland, United States +2 more locations

Active Not RecruitingNA1220 miles

Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

NCT00819208

RATIONALE: Participating in a physical activity program designed to increase free time physical activity and receiving written health education materials may influence the chance of cancer recurring as well as impact on physical fitness, psychological well-being and the quality of life of patients who have undergone surgery and chemotherapy for colon cancer. It is not yet known whether giving a physical activity program together with health education materials is more effective than giving health education materials alone for patients who have undergone colon cancer treatment. PURPOSE: This randomized phase III trial is studying a physical activity program given together with health education materials to see how well it works compared with giving health education materials alone for patients who have undergone treatment for high-risk stage II or stage III colon cancer.

Anxiety DisorderCognitive/Functional EffectsColorectal Cancer+5 more

Canadian Cancer Trials Group889 participantsStarted Jun 2009

Detroit, Michigan, United States • Lebanon, New Hampshire, United States • Chapel Hill, North Carolina, United States +44 more locations

PreviousPage 2 of 9Next

Other Conditions in Phoenix

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia